Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT04970238

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
  • Zhijun Sun Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04970238
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04970238. Randomized; double masking; primary purpose prevention. Start 2021-10 (anticipated); primary completion 2023-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
Condition
ST Elevation Myocardial Infarction
Condition
Heart Failure
Intervention (Drug)
Levosimendan
Intervention (Other)
placebo
Lead sponsor
Zhijun Sun (class: other)

Record details

Record id
cardio:ct-nct04970238
Content hash
7c8812b4a1cba96edb69e12cbee1db29f01127e8332e16ed40d71bf71956d481